tetano
Editor, Senior Moderator
Front Cell Infect Microbiol. 2019 Mar 26;9:67. doi: 10.3389/fcimb.2019.00067. eCollection 2019.
[h=1]Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors.[/h] Radosevic D[SUP]1[/SUP], Sencanski M[SUP]1[/SUP], Perovic V[SUP]1[/SUP], Veljkovic N[SUP]1[/SUP], Prljic J[SUP]1[/SUP], Veljkovic V[SUP]2[/SUP], Mantlo E[SUP]3[/SUP], Bukreyeva N[SUP]3[/SUP], Paessler S[SUP]3,[/SUP][SUP]4[/SUP], Glisic S[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza A virus (IAV) matrix protein 2 (M2), an ion channel, is crucial for virus infection, and therefore, an important anti-influenza drug target. Adamantanes, also known as M2 channel blockers, are one of the two classes of Food and Drug Administration-approved anti-influenza drugs, although their use was discontinued due to prevalent drug resistance. Fast emergence of resistance to current anti-influenza drugs have raised an urgent need for developing new anti-influenza drugs against resistant forms of circulating viruses. Here we propose a simple theoretical criterion for fast virtual screening of molecular libraries for candidate anti-influenza ion channel inhibitors both for wild type and adamantane-resistant influenza A viruses. After in silico screening of drug space using the EIIP/AQVN filter and further filtering of drugs by ligand based virtual screening and molecular docking we propose the best candidate drugs as potential dual inhibitors of wild type and adamantane-resistant influenza A viruses. Finally, guanethidine, the best ranked drug selected from ligand-based virtual screening, was experimentally tested. The experimental results show measurable anti-influenza activity of guanethidine in cell culture.
[h=4]KEYWORDS:[/h] IAV matrix protein 2; drug repurposing; drug resistance; influenza A; virtual screening
PMID: 30972303 PMCID: PMC6443897 DOI: 10.3389/fcimb.2019.00067
Free full text
[h=1]Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors.[/h] Radosevic D[SUP]1[/SUP], Sencanski M[SUP]1[/SUP], Perovic V[SUP]1[/SUP], Veljkovic N[SUP]1[/SUP], Prljic J[SUP]1[/SUP], Veljkovic V[SUP]2[/SUP], Mantlo E[SUP]3[/SUP], Bukreyeva N[SUP]3[/SUP], Paessler S[SUP]3,[/SUP][SUP]4[/SUP], Glisic S[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza A virus (IAV) matrix protein 2 (M2), an ion channel, is crucial for virus infection, and therefore, an important anti-influenza drug target. Adamantanes, also known as M2 channel blockers, are one of the two classes of Food and Drug Administration-approved anti-influenza drugs, although their use was discontinued due to prevalent drug resistance. Fast emergence of resistance to current anti-influenza drugs have raised an urgent need for developing new anti-influenza drugs against resistant forms of circulating viruses. Here we propose a simple theoretical criterion for fast virtual screening of molecular libraries for candidate anti-influenza ion channel inhibitors both for wild type and adamantane-resistant influenza A viruses. After in silico screening of drug space using the EIIP/AQVN filter and further filtering of drugs by ligand based virtual screening and molecular docking we propose the best candidate drugs as potential dual inhibitors of wild type and adamantane-resistant influenza A viruses. Finally, guanethidine, the best ranked drug selected from ligand-based virtual screening, was experimentally tested. The experimental results show measurable anti-influenza activity of guanethidine in cell culture.
[h=4]KEYWORDS:[/h] IAV matrix protein 2; drug repurposing; drug resistance; influenza A; virtual screening
PMID: 30972303 PMCID: PMC6443897 DOI: 10.3389/fcimb.2019.00067
Free full text